Healthcare innovation and patent law's 'pharmaceutical privilege': is there a pharmaceutical privilege? And if so, should we remove it?
This article reviews current trends in patent claims regarding personalised, stratified and precision medicine. These trends are not particularly well understood by policymakers, even less by the public, and are quite recent. Consequently, their implications for the public interest have hardly... Full description
|1st Person:||Graham Dutfield|
in Health economics, policy and law Vol. 12, No. 4 (2017), p. 453
|Type of Publication:||Article|